Menu
← Oncology Approval Tracker
FDA DECISION ·
Noxafil PowderMix
posaconazole delayed-release oral suspension · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Prophylaxis against invasive Aspergillus and Candida infections for high-risk children age 2 and older weighing 40 kg or less, including recipients of hematopoietic stem cell transplantation with GVHD and children with hematologic malignancy and prolonged chemotherapy-related neutropenia.
LAMPGEN ANALYSIS
Why it matters
The delayed-release suspension supplies a weight-defined pediatric formulation for patients at high risk of invasive fungal disease.
What research teams should watch
Check age and weight, record the specific posaconazole formulation and plan drug-interaction and administration checks.
PRIMARY RECORDS